Moleculin Biotech, Inc. — 2016 Form 10-K Summary
Business context and period. This is the annual report for the year ended December 31, 2016, not a standalone fourth-quarter report. Moleculin is a preclinical oncology drug developer with no approved products or product sales. Its lead candidate is liposomal Annamycin for relapsed or refractory acute myeloid leukemia (AML); its earlier-stage programs are the WP1066 and WP1122 portfolios.
Financial performance and position
| Metric | FY 2016 | Prior comparable information |
|---|---|---|
| Revenue | $0 | $0; 2015 covers inception on July 28 through year-end |
| Research and development expense | $1.50 million | $0.26 million |
| General and administrative expense | $2.38 million | $0.48 million |
| Total operating expense / operating loss | $3.88 million / $(3.88) million | $0.74 million / $(0.74) million |
| Net loss | $(3.93) million; $(0.40) per share | $(0.75) million; $(0.13) per share |
| Cash used in operating activities | $3.76 million | $0.42 million |
| Cash and cash equivalents at year-end | $5.01 million | $0.03 million |
| Current assets / current liabilities | $5.22 million / $1.35 million | $0.03 million / $0.77 million |
| Total liabilities | $1.43 million | $0.77 million |
There was no product revenue, so gross margin is not applicable. The net loss included approximately $450,000 of identified noncash expenses, including stock-based compensation, depreciation, and a one-time former CFO severance expense. Research and development spending increased as the company prepared for clinical development; general and administrative costs rose with staffing, professional services, public-company expenses, and insurance.
Net cash provided by financing was $8.87 million, largely from the IPO. Investing cash outflow was $121,000, mainly related to the Moleculin, LLC acquisition. Year-end convertible notes payable were $296,000, with $20,000 of accrued interest included in the balance-sheet amount; remaining convertible principal could convert into approximately 1.82 million shares. No dividends were paid or expected in the foreseeable future.
Material changes and developments
- Net loss increased from the 2015 inception period as operations expanded; the periods are not directly comparable because 2015 includes only part of a year and the 2016 statements include Moleculin, LLC from its May 2016 acquisition.
- Cash increased following the May 2016 IPO, which generated $8.46 million in net proceeds, and other equity financing. The company reported approximately $5.01 million cash at year-end.
- In February 2017, after the reporting date, the company raised approximately $4.4 million net in a public offering of shares and warrants. It also reported approximately $800,000 gross proceeds from subsequent exercise of about 600,000 short-term warrants.
- Management estimated that year-end cash plus the February offering proceeds would fund planned operations into the first quarter of 2018. The estimate assumed no significant warrant-exercise proceeds; management said increased spending or faster development could shorten the runway.
- The company recorded $11.15 million of acquired in-process research and development intangible assets, principally associated with WP1066. An impairment or abandonment of development could result in a material noncash write-off.
Outlook, risks, and unusual items
- Annamycin: The company filed a new IND in February 2017, but withdrew it after FDA requested protocol revisions, additional information, and further chemistry, manufacturing, and controls data. Management expected to resubmit in time for a possible first-half 2017 trial start, subject to timely completion of CMC work. The revised plan adds a Phase I dose-finding arm, cost, and several months to development; management anticipated trial results sometime in 2018. These are expectations, not assured outcomes.
- The company said prior Annamycin studies involved 114 patients and reported little to no cardiotoxicity, but those studies were conducted by prior developers and do not establish future safety or efficacy. Two patients in a prior study died of tumor lysis syndrome. Annamycin received FDA Orphan Drug designation for AML in March 2017; designation is not marketing approval.
- Other programs: WP1066 remains early-stage; a physician-sponsored IND for brain tumors was reportedly on hold pending GMP production documentation, and Moleculin does not control that effort. WP1122 had encouraging preliminary mouse toxicology results, but substantial preclinical and clinical work remains.
- Funding and going concern: The auditor and financial-statement notes state that accumulated losses, no operating revenue, and dependence on future financing raise substantial doubt about the company’s ability to continue as a going concern. Management’s cash-runway estimate does not fund full development or commercialization. Additional capital may be required and may not be available on acceptable terms.
- Intellectual property and agreements: Annamycin’s composition-of-matter patent protection has expired; planned formulation, process, and use patent applications may not be granted or enforceable. WP1066 rights are subject to an HPI arrangement: the company may buy back HPI’s rights for $1.0 million within the stated period; otherwise, the license can become exclusive to HPI. The company also disclosed related-party transactions that were not negotiated at arm’s length.
- Controls and reporting: Management concluded internal control over financial reporting was ineffective due to inadequate segregation of duties, a material weakness. Disclosure controls were also deemed ineffective. A separate business-combination accounting error led to restatement of the June 2016 quarterly filing; management reported remediation efforts for that issue but not the segregation-of-duties weakness.
- Other principal risks include clinical and regulatory failure or delay, reliance on third-party manufacturers and collaborators, competition, future dilution, and the possibility of impairment of acquired IPR&D. The company reported no pending legal proceedings.
Important facts for investors to verify
- Current cash, burn rate, and financing runway against actual development costs and any warrant exercises after the offering.
- Status of Annamycin’s IND resubmission, outstanding CMC work, FDA feedback, and the timing and design of any trial.
- Whether management has remediated the segregation-of-duties material weakness and strengthened financial reporting controls following the prior restatement.
- Terms, deadlines, and funding feasibility for the HPI buyout, and the implications if WP1066 rights revert to an exclusive HPI license.
- Valuation assumptions supporting the $11.15 million IPR&D asset and the risk of impairment if programs are delayed, changed, or discontinued.
- Potential dilution from convertible notes, outstanding warrants, equity awards, and future capital raises; reported common shares outstanding were 12.16 million at year-end and 17.18 million as of March 24, 2017.